BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 29975184)

  • 1. Elevated antibodies against Epstein-Barr virus among individuals predicted to carry nasopharyngeal carcinoma susceptibility variants.
    Coghill AE; Hsu WL; Yang Q; Wang CP; Lou PJ; Yu KJ; Yu G; Diehl SR; Chen CJ; Goldstein AM; Hildesheim A
    J Gen Virol; 2018 Sep; 99(9):1268-1273. PubMed ID: 29975184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epstein-Barr virus seroreactivity among unaffected individuals within high-risk nasopharyngeal carcinoma families in Taiwan.
    Pickard A; Chen CJ; Diehl SR; Liu MY; Cheng YJ; Hsu WL; Sun B; Hsu MM; Chen IH; Chen JY; Yang CS; Mittl BL; Chou SP; Ruggles DD; Goldstein AM; Hildesheim A
    Int J Cancer; 2004 Aug; 111(1):117-23. PubMed ID: 15185352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High Levels of Antibody that Neutralize B-cell Infection of Epstein-Barr Virus and that Bind EBV gp350 Are Associated with a Lower Risk of Nasopharyngeal Carcinoma.
    Coghill AE; Bu W; Nguyen H; Hsu WL; Yu KJ; Lou PJ; Wang CP; Chen CJ; Hildesheim A; Cohen JI
    Clin Cancer Res; 2016 Jul; 22(14):3451-7. PubMed ID: 26920891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic utility of anti-EBV antibody testing for defining NPC risk among individuals from high-risk NPC families.
    Yu KJ; Hsu WL; Pfeiffer RM; Chiang CJ; Wang CP; Lou PJ; Cheng YJ; Gravitt P; Diehl SR; Goldstein AM; Chen CJ; Hildesheim A
    Clin Cancer Res; 2011 Apr; 17(7):1906-14. PubMed ID: 21447725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Role of Epstein-Barr Virus DNA Load and Serology as Screening Tools for Nasopharyngeal Carcinoma.
    Tay JK; Chan SH; Lim CM; Siow CH; Goh HL; Loh KS
    Otolaryngol Head Neck Surg; 2016 Aug; 155(2):274-80. PubMed ID: 27143706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Seroprevalence of IgA anti Epstein-Barr virus is high among family members of nasopharyngeal cancer patients and individuals presenting with chronic complaints in head and neck area.
    Hutajulu SH; Fachiroh J; Argy G; Indrasari SR; Indrawati LPL; Paramita DK; Jati TBR; Middeldorp JM
    PLoS One; 2017; 12(8):e0180683. PubMed ID: 28800616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distribution of Epstein-Barr viral load in serum of individuals from nasopharyngeal carcinoma high-risk families in Taiwan.
    Yang X; Goldstein AM; Chen CJ; Rabkin CS; Chen JY; Cheng YJ; Hsu WL; Sun B; Diehl SR; Liu MY; Walters M; Shao W; Ortiz-Conde BA; Whitby D; Elmore SH; Gulley ML; Hildesheim A
    Int J Cancer; 2006 Feb; 118(3):780-4. PubMed ID: 16106400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-assay combination of Epstein-Barr Virus (EBV) EBNA1- and viral capsid antigen-p18-derived synthetic peptides for measuring anti-EBV immunoglobulin G (IgG) and IgA antibody levels in sera from nasopharyngeal carcinoma patients: options for field screening.
    Fachiroh J; Paramita DK; Hariwiyanto B; Harijadi A; Dahlia HL; Indrasari SR; Kusumo H; Zeng YS; Schouten T; Mubarika S; Middeldorp JM
    J Clin Microbiol; 2006 Apr; 44(4):1459-67. PubMed ID: 16597877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma.
    Shao JY; Li YH; Gao HY; Wu QL; Cui NJ; Zhang L; Cheng G; Hu LF; Ernberg I; Zeng YX
    Cancer; 2004 Mar; 100(6):1162-70. PubMed ID: 15022282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated Epstein-Barr virus seroreactivity among unaffected members of families with nasopharyngeal carcinoma.
    Qin HD; Jia WH; Zhang LL; Liu N; Zhou XX; Wang MH; Feng QS; Chen LZ; Zhang Y; Jorgensen TJ; Zeng YX; Shugart YY
    J Med Virol; 2011 Oct; 83(10):1792-8. PubMed ID: 21837797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epstein-Barr virus serology as a potential screening marker for nasopharyngeal carcinoma among high-risk individuals from multiplex families in Taiwan.
    Coghill AE; Hsu WL; Pfeiffer RM; Juwana H; Yu KJ; Lou PJ; Wang CP; Chen JY; Chen CJ; Middeldorp JM; Hildesheim A
    Cancer Epidemiol Biomarkers Prev; 2014 Jul; 23(7):1213-9. PubMed ID: 24769890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of commercial EBV RecombLine assay for diagnosis of nasopharyngeal carcinoma.
    Paramita DK; Fachiroh J; Haryana SM; Middeldorp JM
    J Clin Virol; 2008 Aug; 42(4):343-52. PubMed ID: 18455473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Seroreactivity against Epstein-Barr virus (EBV) among first-degree relatives of sporadic EBV-associated nasopharyngeal carcinoma in Indonesia.
    Hutajulu SH; Ng N; Jati BR; Fachiroh J; Herdini C; Hariwiyanto B; Haryana SM; Middeldorp JM
    J Med Virol; 2012 May; 84(5):768-76. PubMed ID: 22431025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of plasma Epstein-Barr virus DNA load to distinguish nasopharyngeal carcinoma patients from healthy high-risk populations in Southern China.
    Ji MF; Huang QH; Yu X; Liu Z; Li X; Zhang LF; Wang P; Xie SH; Rao HL; Fang F; Guo X; Liu Q; Hong MH; Ye W; Zeng YX; Cao SM
    Cancer; 2014 May; 120(9):1353-60. PubMed ID: 24477877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of association between cigarette smoking and Epstein Barr virus reactivation in the nasopharynx in people with elevated EBV IgA antibody titres.
    Chen Y; Xu Y; Zhao W; Xiao X; Zhou X; Lin L; Huang T; Liao J; Li Y; Zeng X; Huang G; Ye W; Zhang Z
    BMC Cancer; 2018 Feb; 18(1):190. PubMed ID: 29444646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a Novel, EBV-Based Antibody Risk Stratification Signature for Early Detection of Nasopharyngeal Carcinoma in Taiwan.
    Coghill AE; Pfeiffer RM; Proietti C; Hsu WL; Chien YC; Lekieffre L; Krause L; Teng A; Pablo J; Yu KJ; Lou PJ; Wang CP; Liu Z; Chen CJ; Middeldorp J; Mulvenna J; Bethony J; Hildesheim A; Doolan DL
    Clin Cancer Res; 2018 Mar; 24(6):1305-1314. PubMed ID: 29301829
    [No Abstract]   [Full Text] [Related]  

  • 17. Genetic variants in NKG2D axis and susceptibility to Epstein-Barr virus-induced nasopharyngeal carcinoma.
    Viet NH; Trung NQ; Dong LT; Trung LQ; Espinoza JL
    J Cancer Res Clin Oncol; 2021 Mar; 147(3):713-723. PubMed ID: 33392659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serologic Profiling Using an Epstein-Barr Virus Mammalian Expression Library Identifies EBNA1 IgA as a Prediagnostic Marker for Nasopharyngeal Carcinoma.
    Paudel S; Warner BE; Wang R; Adams-Haduch J; Reznik AS; Dou J; Huang Y; Gao YT; Koh WP; Bäckerholm A; Yuan JM; Shair KHY
    Clin Cancer Res; 2022 Dec; 28(23):5221-5230. PubMed ID: 36165913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Assessment of detection assays of Epstein-Barr viral Rta-IgG, VCA-IgA, EA-IgA and Epstein-Barr viral DNA at different clinical stages in the diagnosis of nasopharyngeal carcinoma].
    Luo YL; Chen H; Peng SG; Lin JH; Huang PY
    Zhonghua Yi Xue Za Zhi; 2013 Nov; 93(44):3516-9. PubMed ID: 24521892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epstein-Barr virus directed screening for nasopharyngeal carcinoma in individuals with positive family history: A systematic review.
    Chow JCH; Lee AWM; Wong CHL; Ng WT; Liu Z; Tay JK; Loh KS; Pace-Asciak P; Cohen O; Corry J; Rodrigo JP; Tsang RKY; Lopez F; Saba NF; de Bree R; Ferlito A
    Oral Oncol; 2022 Oct; 133():106031. PubMed ID: 35908365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.